PacBio sequencing reagents

The National Institutes of Health Office of Legislative and Congressional Affairs, under the Department of Health and Human Services, has issued a notice of intent to award a Firm-Fixed-Price Purchase Order for PacBio sequencing reagents exclusively to Pacific Biosciences of California, Inc., due to the proprietary nature of the required materials. The reagents, which include SMRT cells and specialized library reagents with proprietary adapters and enzymes, are essential for operation of the Revio sequencing platform at the NIH Intramural Sequencing Center in Rockville, Maryland, where high-throughput, long-read DNA and RNA sequencing is conducted. The procurement is structured as a Total Small Business Set-Aside under FAR 19.5, identified by NAICS code 325414, and is open to small businesses including 8(a), service-disabled veteran owned, HUBZone, small disadvantaged, veteran-owned, and women-owned entities, which may submit a written capability statement to demonstrate their ability to perform the work. Despite the set-aside designation, the government has explicitly stated this is not a request for competitive quotes and intends to award to the sole provider unless responses received prompt a discretionary decision to open competition. The opportunity was posted on June 24, 2026, and responses must be submitted via email to david.shen@nih.gov no later than 11:00 p.m. EDT on July 2, 2026. No pricing, delivery schedule, inspection criteria, packaging requirements, or contract duration have been disclosed in the notice. The contract will be performed at Rockville, Maryland, with no specification of FOB terms, payment office, or contracting officer representative. All reagents must be fully compatible with the Revio instrument platform.